AirSculpt Technologies, a medical technology company specializing in minimally invasive body contouring, has returned to same-store sales growth after more than two years of declines, executives said. The company outlined plans to expand services tied to GLP-1 weight-loss drug side effects and eventually resume clinic growth across the U.S.
Chief Executive Officer Yogi Jashnani described AirSculpt as a “premier body contouring service provider” offering fat removal, fat transfer, and skin tightening procedures across 31 corporate centers. The company generates about $150 million in revenue, with an approximately 10% EBITDA margin and 60% gross margin.
Jashnani said AirSculpt’s procedures are minimally invasive and performed without scalpels, stitches, or general anesthesia. Patients are awake during procedures, which are performed under local anesthesia through a 2-millimeter or smaller opening. The company’s average procedure costs about $12,000 to $13,000, is paid entirely in cash, and is not covered by insurance.
Jashnani highlighted GLP-1 weight-loss drug users as a potential growth market for AirSculpt, saying the company is not seeking to sell GLP-1 medications but instead address aesthetic issues that can follow weight loss. He cited McKinsey data showing GLP-1 users rising from 5 million in 2023 to an estimated 25 million users. Jashnani said 60% to 70% of users may experience side effects such as loose skin or remaining stubborn fat deposits. He said AirSculpt’s targeted fat removal and skin procedures can help patients “complete their aesthetic journey.”
The company expanded into standalone skin tightening in the middle of last year, after previously performing skin tightening alongside fat removal and fat transfer procedures. In the fourth quarter, AirSculpt also began piloting skin removal procedures for patients with more significant loose skin. Jashnani said the company performed about 100 skin removal surgeries in the fourth quarter and about 150 in the first quarter.
In response to an analyst question, Jashnani said AirSculpt uses helium plasma technology for skin tightening, specifically Apyx Medical’s Renuvion device, and also performs skin excisions as part of the pilot program.
**Executives See Room for More U.S. Clinics**
Jashnani said AirSculpt currently operates 31 centers, roughly one in each major metropolitan area where it has a presence, but believes it could add another 100 U.S. locations without significant cannibalization. He named Tampa, Indianapolis, Long Island, and Portland as examples of markets where the company does not currently operate.
He said AirSculpt previously opened five new locations annually and has a track record with de novo centers, many of which have paid back within a year. During the question-and-answer portion, executives said the company leases all clinics, usually in medical centers, and that it costs roughly $1 million to build out a clinic.
Executives said AirSculpt performs all procedures in its own facilities and does not use third-party surgery centers. Chief Financial Officer Michael Arthur said the company’s cost of service is about 40% of revenue, including roughly 20% paid to physicians under revenue-sharing agreements, about 15% for nursing and medical supplies, and lease costs of about 5%.
**Company Points to Marketing Changes Behind Sales Improvement**
Jashnani said AirSculpt’s core customer is typically a woman between 35 and 55 years old with household income above $100,000 who is “looking to invest in herself.” The company’s centers are located in metropolitan areas and high-end retail corridors, including near The Plaza in New York City and off Rodeo Drive in Los Angeles.
AirSculpt’s recent improvement has been driven in part by changes to its direct-to-consumer marketing strategy. Jashnani said the company engages potential patients through paid media, paid social, paid search, influencers, and word of mouth, then uses a consultative sales process to build custom treatment packages with surgeons.
“Over the last year or so, we've been able to drive revenue growth by optimizing where we are spending our marketing dollars,” Jashnani said, citing improvements in channel selection, targeting, and outreach. He said same-store sales improved from negative levels to a positive 1% comparable sales result in the first quarter, the company’s first positive quarter in more than two years.
For 2026, Jashnani said the company has provided guidance with a midpoint reflecting roughly 2.5% same-store sales growth and adjusted EBITDA growth of about 28% at the midpoint.
**Balance Sheet and Operations Update**
Chief Financial Officer Michael Arthur said the company has reduced debt from roughly $75 million at the start of last year to $46 million at the end of the first quarter. Cash increased over that period, with AirSculpt ending the first quarter of 2026 with about $16.7 million in cash.
Arthur said AirSculpt’s net debt-to-EBITDA leverage ratio is now below 2.5 times, giving the company more flexibility to reinvest in the business. He said the company is focused on refinancing its current debt, which comes current in the second quarter of 2026, and expects to provide an update during its second-quarter earnings call in August.
Source: Read the original report | Published: May 19, 2026